Harpoon Therapeutics, Inc.

NasdaqCM:HARP Stock Report

Market Cap: US$492.3m

Harpoon Therapeutics Future Growth

Future criteria checks 2/6

Harpoon Therapeutics is forecast to grow earnings and revenue by 10.6% and 35.3% per annum respectively. EPS is expected to grow by 25.7% per annum. Return on equity is forecast to be -220.2% in 3 years.

Key information

10.6%

Earnings growth rate

25.7%

EPS growth rate

Biotechs earnings growth20.6%
Revenue growth rate35.3%
Future return on equity-220.2%
Analyst coverage

Good

Last updated11 Mar 2024

Recent future growth updates

Recent updates

Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Jan 30
Improved Revenues Required Before Harpoon Therapeutics, Inc. (NASDAQ:HARP) Stock's 97% Jump Looks Justified

Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Oct 01
Harpoon Therapeutics, Inc. (NASDAQ:HARP) Looks Inexpensive After Falling 55% But Perhaps Not Attractive Enough

Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Aug 14
Analysts Just Made A Notable Upgrade To Their Harpoon Therapeutics, Inc. (NASDAQ:HARP) Forecasts

Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

May 28
Forecast: Analysts Think Harpoon Therapeutics, Inc.'s (NASDAQ:HARP) Business Prospects Have Improved Drastically

Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Mar 11
Harpoon Therapeutics (NASDAQ:HARP) Will Have To Spend Its Cash Wisely

Harpoon Therapeutics appoints Luke Walker as CMO

Oct 04

Harpoon Therapeutics: A Well Undervalued Tri-Specific Oncology Player

Sep 01

Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Jul 30
Here's Why We're A Bit Worried About Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Situation

Harpoon Therapeutics: A T-Cell Engager Platform And A Negative Enterprise Value Makes It A Candidate For My 'Bio Boom' Portfolio

Jul 07

Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

Mar 08
Is Harpoon Therapeutics (NASDAQ:HARP) In A Good Position To Invest In Growth?

We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Nov 30
We're Keeping An Eye On Harpoon Therapeutics' (NASDAQ:HARP) Cash Burn Rate

Harpoon Therapeutics: A First Look

Sep 16

Harpoon shares slide after early-stage prostate cancer study data fails to impress

Jun 04

Earnings and Revenue Growth Forecasts

NasdaqCM:HARP - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/202647-76-67-945
12/31/202523-67-54-648
12/31/202421-56-33-518
12/31/202338-26-16-408
9/30/202337-30-69-69N/A
6/30/202347-40-77-77N/A
3/31/202335-59-84-83N/A
12/31/202232-68-90-89N/A
9/30/202232-71-88-88N/A
6/30/202223-76-84-84N/A
3/31/202221-75-129-129N/A
12/31/202124-117-122-122N/A
9/30/202127-107-121-120N/A
6/30/202126-103-114-113N/A
3/31/202123-99-10-9N/A
12/31/202017-50-9-9N/A
9/30/202012-533940N/A
6/30/202010-554043N/A
3/31/20208-55-11-8N/A
12/31/20196-56-6-3N/A
9/30/20195-51-46-43N/A
6/30/20194-42-41-39N/A
3/31/20194-36-33-32N/A
12/31/20185-27-28-27N/A
9/30/20184-23-9-8N/A
12/31/20171-17-12N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: HARP is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: HARP is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: HARP is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: HARP's revenue (35.3% per year) is forecast to grow faster than the US market (8.1% per year).

High Growth Revenue: HARP's revenue (35.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: HARP is forecast to be unprofitable in 3 years.


Discover growth companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.